Andy Burnhams Rising Political Influence Could Reshape UK Regional Investment Landscape Fitness Apps Challenge Personal Trainer Industry WSJ Analysis Highlights Flexibility and Injury Risks Trumps Mixed Signals on Iran Deal Keep Oil Markets on Edge as Summer Stockpile Risks Mount Key Factors That Could Deflate the Stock Market Bubble Amazon Names Amwell Cofounder Dr Roy Schoenberg to Lead Health Division as Top Exec Departs New York Fed Study Surging Gas Prices Hit LowerIncome Households Harder Teekay Tankers Q1 2026 Earnings Strong EPS Beat Amidst Challenging Tanker Market FTFT Q2 2024 Earnings Narrowing Losses Amidst Strategic Transformation in Blockchain and Fintech GE Vernova Q1 2026 Earnings Strong EPS Beat Fails to Lift Shares Stock Falls 36 ANI Pharmaceuticals Q1 2026 Earnings Major EPS Beat Belies Subdued Market Response Rand Capital Corporation Q1 2026 Earnings Positive EPS Amid Portfolio Pressures CAKE Q1 2026 Earnings EPS Beats Estimates by 147 Modest Stock Uptick Kiora Pharmaceuticals KPRX Slips 45 as Stock Tests Key Support Level Evolution Petroleum EPM Gains 123 as Shares Test Key Resistance Level GE HealthCare GEHC Holds Steady Near Resistance as Volume Signals Caution SORNW Holds Steady at 028 as Support and Resistance Levels Narrow Flaherty Crumrine Total Return Fund FLC Holds Steady Near Key Support as YieldSeeking Investors Weigh Options Asian Stocks Poised for Gains Amid Iran Deal Optimism INTC Q1 2026 Earnings Earnings Surge on Massive EPS Beat Amidst Revenue Uncertainty Horizon Bancorp HBNC Gains Ground as Price Nears Key Resistance BTC Digital Ltd BTCT Q4 2024 Earnings EPS Surprises with a Positive 010 Against a 019 Loss Estimate Waystar Holding Corp WAY Q1 2026 Earnings EPS Surpasses Estimates Shares Gain 39 CRGO Q1 2026 Earnings EPS Misses Estimates by Nearly 70 No Revenue Reported Stock Slides 574 FTNT Q1 2026 Earnings EPS Surges Past Estimates Revenue Details Unavailable Hut 8 Corp HUT Q3 2024 Earnings EPS Beats Estimates Despite Continued Losses ARTNA Q3 2025 Earnings Slight EPS Beat Amid Steady Utility Performance NervGen Pharma Q3 2025 Earnings Narrowed Loss Meets Estimates But Stock Plunges 43